Project Grant R01AI192204
- This Project Grant award of $797,734 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), is funding research on the effects of doxycycline on inflammation and the microbiome. The research aims to investigate whether doxycycline post-exposure prophylaxis (doxy-PEP) could play a beneficial role in reducing systemic and gut inflammation among men who have sex with men (MSM) and transgender...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) provides $200,824 to The Miriam Hospital in Rhode Island to develop and pilot-test an AI-based chatbot intervention. The goal is to promote the use of doxycycline as post-exposure prophylaxis (Doxy-PEP) to prevent bacterial sexually transmitted infections, including syphilis, gonorrhea, and chlamydia, among men...
- The federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) is providing $209,757 to The Trustees of Columbia University in the City of New York, Health Sciences Division, from September 15, 2025 to August 31, 2030. The funding supports mentorship and training to develop a new cadre of researchers focused on addressing the challenges of multidrug-resistant tuberculosis (MDR-TB) within the global HIV...
- This Project Grant award of $3,210,845.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop methods for the real-time detection of Staphylococcus aureus transmission in hospital settings. The key products and services to be delivered under this award include: Integrating weekly patient colonization sampling with hospital-wide genomic surveillance to analyze phylogenetic relationships among S. aureus strains, in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $244,870 to the University of Washington to evaluate vaccination and antibiotic prophylaxis strategies for preventing Chlamydia trachomatis (CT) infections at the population level. The project aims to 1) assess the frequency and characteristics of antibiotic use among individuals eligible for prophylaxis, and 2)...
- This federal Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $223,550 to the Icahn School of Medicine at Mount Sinai to conduct a pilot feasibility trial evaluating the impact of a point-of-care sexually transmitted infection (STI) testing strategy on improving HIV prevention service delivery in adolescents. The research aims to assess whether point-of-care testing for gonorrhea and chlamydia can...
- This federal Project Grant award for $657,907 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a 5-year longitudinal analysis to understand the impact of expanding pharmacists' scope of practice on the uptake and retention of pre-exposure prophylaxis (PrEP) for HIV prevention. The project aims to integrate multiple data sources, including policy, census, survey, and medical claims data, to...
- The University of Chicago received a $126,435 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to pilot the implementation of electronic patient-reported sexual health data into electronic medical records (EMRs) to identify individuals who would benefit from pre-exposure prophylaxis (PrEP) for HIV prevention. The project, titled "INFOHIV: Clinical Informatics for Optimizing HIV Prevention and...
- This Project Grant award of $2,944,529 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand resistance and tolerance to the tuberculosis (TB) drugs pretomanid (PA) and delamanid (DLM) in Mycobacterium tuberculosis (MTB). The goal is to apply innovative genome-wide screens to identify the MTB genes that determine PA/DLM potency, analyze the key resistance determinant...
- This Project Grant award of $115,123 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to reveal strategies for eradicating antibiotic-tolerant Staphylococcus aureus persister cells. The research aims to identify the host cells harboring intracellular S. aureus reservoirs and characterize the host and bacterial transcriptomes using single-cell approaches. Additionally, the project...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $837,463 to Columbia University to conduct a comprehensive assessment of antimicrobial resistance and engagement with doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of sexually transmitted infections (STIs). The key objectives are to: (1) create a prospective cohort of 500 participants to examine factors associated with Doxy-PEP care engagement and effective use; (2) evaluate the impact of antimicrobial resistance in Doxy-PEP users through biological sample collection and analysis; and (3) assess the potential for transmission of bacteria between sexual partners. This research aims to provide valuable insights into the risks, benefits, implementation, and impact of Doxy-PEP to inform future strategies for optimizing STI prevention while minimizing antimicrobial resistance risks. The award period runs from August 4, 2025 to July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $837.5k | 8/4/25 |